Immix Biopharma Inc
IMMX6.740USD
+0.790+13.28%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
222.66MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immix Biopharma Inc Unternehmen
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc Informationen
BörsenkürzelIMMX
Name des UnternehmensImmix Biopharma Inc
IPO-datumDec 16, 2021
CEORachman (Ilya)
Anzahl der mitarbeiter18
WertpapierartOrdinary Share
GeschäftsjahresendeDec 16
Addresse11400 West Olympic Blvd.
StadtLOS ANGELES
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl90064
Telefon18889581084
Websitehttps://immixbio.com/
BörsenkürzelIMMX
IPO-datumDec 16, 2021
CEORachman (Ilya)
Führungskräfte von Immix Biopharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
Andere
78.17%
Aktionäre
Aktionäre
Anteil
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
Andere
78.17%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
16.64%
Corporation
6.21%
Investment Advisor
5.13%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.21%
Venture Capital
0.07%
Research Firm
0.05%
Andere
70.69%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
69
3.66M
7.01%
-955.81K
2025Q3
60
2.79M
8.55%
-1.92M
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hsu (Jason)
4.86M
9.32%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
6.21%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
2.19%
+746.00
+0.07%
Dec 10, 2025
The Vanguard Group, Inc.
730.16K
1.4%
+31.63K
+4.53%
Sep 30, 2025
Ng (Carey)
1.05M
2%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
1.63%
--
--
Sep 30, 2025
Chang (Nancy T)
421.94K
1.29%
+421.94K
--
Sep 08, 2025
Morris (Gabriel S)
586.41K
1.12%
+770.00
+0.13%
Dec 10, 2025
Geode Capital Management, L.L.C.
187.48K
0.36%
+26.36K
+16.36%
Sep 30, 2025
Adams (Helen C)
174.75K
0.34%
-227.00
-0.13%
Apr 22, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
